Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05909059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAR T-cell Therapy in Patients With Renal Dysfunction

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Aug 31, 2026 → Dec 31, 2026
See other at-risk trials from Northside Hospital, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 7 words
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Aug 31, 2025 to Aug 31, 2026
    • Study completion date: Aug 31, 2026 to Aug 31, 2027
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 31, 2024 to Nov 18, 2024
    • Site details revised
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Jun 30, 2024 to Oct 31, 2024v4
  2. Start date: Dec 31, 2023 to Jun 30, 2024v3
  3. Start date: Aug 31, 2023 to Dec 31, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Northside Hospital, Inc.
9 trials monitored
See 4 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
Multiple Myeloma
1,261 trials monitored
See 80 trials at risk
and 1 more disease
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Trial Details
NCT Number NCT05909059
Lead Sponsor Northside Hospital, Inc.
Collaborators: Blood and Marrow Transplant Group of Georgia
Conditions
(from sponsor)		 Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
Related terms Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov